Post by rachelcarson1953 on Oct 14, 2020 22:41:21 GMT
Regeneron has developed drug for treatment of Ebola!
www.msn.com/en-us/news/us/regeneron-s-drug-becomes-first-fda-approved-ebola-virus-treatment/ar-BB1a1TAP?ocid=msedgdhp
Honestly, I thought Ebola might be the pathogen that could seriously threaten the human race.
The first documented outbreak of Ebola was in Africa in the area of Yambuku, and the subject of study by leading CDC and WHO researchers. The case fatality rate was essentially 100% at first, then in a later outbreak, convalescent serum provided some treatment.
It is a spectacularly gory hemorrhagic disease.
Link for further reading:
www.cdc.gov/vhf/ebola/history/summaries.html
www.msn.com/en-us/news/us/regeneron-s-drug-becomes-first-fda-approved-ebola-virus-treatment/ar-BB1a1TAP?ocid=msedgdhp
Honestly, I thought Ebola might be the pathogen that could seriously threaten the human race.
(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' triple antibody cocktail as the first Ebola virus treatment, lending validation to similar drugs being developed for COVID-19.
Regeneron's Inmazeb, an intravenous drug, has been approved for adults and children, after it was tested in 382 candidates with confirmed Zaire ebolavirus infection in a clinical trial, the health regulator said.
The drugmaker has said it is talking with the FDA about an emergency use authorization for its experimental dual antibody cocktail for COVID-19, which was given to U.S. President Donald Trump as part of his treatment regime.
The treatments are part of a class of drugs known as monoclonal antibodies, which are manufactured copies of antibodies that are one of the main weapons generated by the immune system to fight infections.
"Today's action demonstrates the FDA's ongoing commitment to responding to public health threats — both domestically and abroad — on the basis of science and data," FDA Commissioner Stephen Hahn said in a media statement.
The FDA approved Ervebo, the first vaccine for the prevention of Ebola virus disease, in December 2019.
(Reporting by Deena Beasley and Vishwadha Chander in Bengaluru; Editing by Shinjini Ganguli)
Regeneron's Inmazeb, an intravenous drug, has been approved for adults and children, after it was tested in 382 candidates with confirmed Zaire ebolavirus infection in a clinical trial, the health regulator said.
The drugmaker has said it is talking with the FDA about an emergency use authorization for its experimental dual antibody cocktail for COVID-19, which was given to U.S. President Donald Trump as part of his treatment regime.
The treatments are part of a class of drugs known as monoclonal antibodies, which are manufactured copies of antibodies that are one of the main weapons generated by the immune system to fight infections.
"Today's action demonstrates the FDA's ongoing commitment to responding to public health threats — both domestically and abroad — on the basis of science and data," FDA Commissioner Stephen Hahn said in a media statement.
The FDA approved Ervebo, the first vaccine for the prevention of Ebola virus disease, in December 2019.
(Reporting by Deena Beasley and Vishwadha Chander in Bengaluru; Editing by Shinjini Ganguli)
It is a spectacularly gory hemorrhagic disease.
Ebola hemorrhagic fever first appeared in Zaire (currently, the Democratic Republic of the Congo or DRC or Congo) in 1976. The original outbreak was in a village named Yambuku near the Ebola River after which the disease was named. During that time, researchers identified the virus in person-to-person contact transmission.
Emergence of Ebola in Humans
Ebola virus disease (EVD), one of the deadliest viral diseases, was discovered in 1976 when two consecutive outbreaks of fatal hemorrhagic fever occurred in different parts of Central Africa. The first outbreak occurred in the Democratic Republic of Congo (formerly Zaire) in a village near the Ebola River, which gave the virus its name. The second outbreak occurred in what is now South Sudan, approximately 500 miles (850 km) away.
Initially, public health officials assumed these outbreaks were a single event associated with an infected person who traveled between the two locations. However, scientists later discovered that the two outbreaks were caused by two genetically distinct viruses: Zaire ebolavirus and Sudan ebolavirus. After this discovery, scientists concluded that the virus came from two different sources and spread independently to people in each of the affected areas.
Viral and epidemiologic data suggest that Ebola virus existed long before these recorded outbreaks occurred. Factors like population growth, encroachment into forested areas, and direct interaction with wildlife (such as bushmeat consumption) may have contributed to the spread of the Ebola virus.
Ebola virus disease (EVD), one of the deadliest viral diseases, was discovered in 1976 when two consecutive outbreaks of fatal hemorrhagic fever occurred in different parts of Central Africa. The first outbreak occurred in the Democratic Republic of Congo (formerly Zaire) in a village near the Ebola River, which gave the virus its name. The second outbreak occurred in what is now South Sudan, approximately 500 miles (850 km) away.
Initially, public health officials assumed these outbreaks were a single event associated with an infected person who traveled between the two locations. However, scientists later discovered that the two outbreaks were caused by two genetically distinct viruses: Zaire ebolavirus and Sudan ebolavirus. After this discovery, scientists concluded that the virus came from two different sources and spread independently to people in each of the affected areas.
Viral and epidemiologic data suggest that Ebola virus existed long before these recorded outbreaks occurred. Factors like population growth, encroachment into forested areas, and direct interaction with wildlife (such as bushmeat consumption) may have contributed to the spread of the Ebola virus.
www.cdc.gov/vhf/ebola/history/summaries.html